← Leaderboards
Onur Cil
University Of California, San Francisco
$2,779,607
Attributed
$2,779,607
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $706.3K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,779,607 · 3
By mechanism
R01$2,408,322 · 2
P30$371,285 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Sarah Monica Knox$17,006,690
- John Alexander Gonzales$1,263,248
- Neel Dave Pasricha$658,029
- Blake Matthew Warner$862,940
- Jennifer K Finley$66,944
Others in their field
Other Emerging Leaders on “Drug Candidate”
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn$46,710,255
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
- Ryan Cirz · Revagenix, Inc.$22,711,751
- Alan D. Palkowitz · Indiana University Indianapolis$17,630,798
Research focus
Drug CandidateTissuesAnimal ModelEfficacy TestingKidneyDoseIn VitroToxic EffectFrequenciesProgramsIn VivoIn Vitro TestingLead CandidateKnockout MicePropertyOralNephrolithiasisPharmaceutical ChemistryEfficacy StudyMetabolicEnteralHyperoxaluriaBiological AvailabilityDrug Kinetics
Grant awards (10)
Roles of CaSR in ocular surface health and disease$410,000
R01 · FY2025 · EY · contact PI
Roles of CaSR in ocular surface health and disease$396,242
R01 · FY2024 · EY · contact PI
SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and Nephrolithiasis$310,080
R01 · FY2024 · DK · contact PI
SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and Nephrolithiasis$323,000
R01 · FY2023 · DK · contact PI
SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and Nephrolithiasis$323,000
R01 · FY2022 · DK · contact PI
Core D: Animal Pharmacology & Models Core$130,405
P30 · FY2022 · DK · contact PI
SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and Nephrolithiasis$323,000
R01 · FY2021 · DK · contact PI
Core D: Animal Pharmacology & Models Core$130,227
P30 · FY2021 · DK · contact PI
SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and Nephrolithiasis$323,000
R01 · FY2020 · DK · contact PI
Core D: Animal Pharmacology & Models Core$110,653
P30 · FY2020 · DK · contact PI